Prakt. lékáren. 2008; 4(6): 271-274

RANIBIZUMAB (LUCENTIS) - A NEW AGENT TO TREAT THE WET FORM OF AGE-RELATED MACULAR DEGENERATION

MUDr. Petr Kolář Ph.D
Oční klinika LF MU a FN, Brno

Ranibizumab (Lucentis®, Novartis) is a recombinant humanized fragment of a monoclonal antibody against vascular endothelial growth factor. It is administered by intraocular injection into

the vitreous humour. It is indicated for treatment of the wet form

of age-related macular degeneration. It is produced

in Escherichia coli cells using recombinant DNA technology.

Keywords: Key words: ranibizumab, age-related macular degeneration, vascular endothelial growth factor, intraocular injection into vitreous humour.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolář P. RANIBIZUMAB (LUCENTIS) - A NEW AGENT TO TREAT THE WET FORM OF AGE-RELATED MACULAR DEGENERATION. Praktické lékárenství. 2008;4(6):271-274.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444. Go to original source... Go to PubMed...
    2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr rev 1997; 18(1): 4-25. Go to original source... Go to PubMed...
    3. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen biding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26(8): 859-870. Go to original source... Go to PubMed...
    4. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267(16): 10931-10934. Go to original source...
    5. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter controlled, multidose study. Ophthalmology 2006; 113(4): 633-642. Go to original source... Go to PubMed...
    6. Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the Cardiovascular Health Study. Ophthalmology 2003; 110: 25-33. Go to original source... Go to PubMed...
    7. Kolář P. Anti-VEGF terapie. In: Kolář P. a kol. Věkem podmíněná makulární degenerace. Praha: Grada 2008; 105-115.
    8. Kolář P. Klasifikace a klinický obraz VPMD. In: Kolář P. a kol. Věkem podmíněná makulární degenerace. Praha: Grada 2008; 59-74.
    9. Kolář, P. Ranibizumab. Farmakoterapie 2007; 5: 431-434.
    10. Kolář P. Věkem podmíněná makulární degenerace. Čas Lék čes 2005; 244: 516-520.
    11. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparison of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999; 27: 536-544. Go to original source... Go to PubMed...
    12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. Go to original source... Go to PubMed...
    13. Sosna T. Epidemiologie a rizikové faktory VPMD. In: Kolář P. a kol. Věkem podmíněná makulární degenerace. Praha: Grada 2008; 51-58.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.